Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease.

Creutzberg CL, Lu KH, Fleming GF.

J Clin Oncol. 2019 Sep 20;37(27):2490-2500. doi: 10.1200/JCO.19.00037. Epub 2019 Aug 12. No abstract available.

PMID:
31403860
2.

Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors.

Wortman BG, Nout RA, Bosse T, Creutzberg CL.

Curr Oncol Rep. 2019 Jul 31;21(9):83. doi: 10.1007/s11912-019-0825-z. Review.

3.

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group.

Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Erratum in: Lancet Oncol. 2019 Sep;20(9):e468.

4.

A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer.

Workel HH, Lubbers JM, Arnold R, Prins TM, van der Vlies P, de Lange K, Bosse T, van Gool IC, Eggink FA, Wouters MCA, Komdeur FL, van der Slikke EC, Creutzberg CL, Kol A, Plat A, Glaire M, Church DN, Nijman HW, de Bruyn M.

Cancer Immunol Res. 2019 May;7(5):784-796. doi: 10.1158/2326-6066.CIR-18-0517. Epub 2019 Mar 14.

PMID:
30872264
5.

Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.

Bagnoli M, Shi TY, Gourley C, Speiser P, Reuss A, Nijman HW, Creutzberg CL, Scholl S, Negrouk A, Brady MF, Hasegawa K, Oda K, McNeish IA, Kohn EC, Oza AM, MacKay H, Millan D, Bennett K, Scott C, Mezzanzanica D.

Cells. 2019 Feb 26;8(3). pii: E200. doi: 10.3390/cells8030200.

6.

Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature.

Boer FL, Ten Eikelder MLG, Kapiteijn EH, Creutzberg CL, Galaal K, van Poelgeest MIE.

Cancer Treat Rev. 2019 Feb;73:91-103. doi: 10.1016/j.ctrv.2018.12.005. Epub 2018 Dec 24. Review.

PMID:
30685613
7.

Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer.

Horeweg N, Creutzberg CL, Rijkmans EC, Laman MS, Velema LA, Coen VLMA, Stam TC, Kerkhof EM, Kroep JR, de Kroon CD, Nout RA.

Int J Gynecol Cancer. 2019 Jan 10. pii: ijgc-2018-000057. doi: 10.1136/ijgc-2018-000057. [Epub ahead of print]

PMID:
30630883
8.

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.

Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group.

Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25.

PMID:
30356126
9.

Cancer of the corpus uteri.

Amant F, Mirza MR, Koskas M, Creutzberg CL.

Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50. doi: 10.1002/ijgo.12612.

PMID:
30306580
10.

Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions.

De Boer SM, Nout RA, Bosse T, Creutzberg CL.

Expert Rev Anticancer Ther. 2019 Jan;19(1):51-60. doi: 10.1080/14737140.2019.1531708. Epub 2018 Oct 24. Review.

PMID:
30295094
11.

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.

Wortman BG, Bosse T, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld H, van den Berg H, Slot A, De Winter KAJ, Verhoeven-Adema KW, Smit VTHBM, Creutzberg CL; PORTEC Study Group.

Gynecol Oncol. 2018 Oct;151(1):69-75. doi: 10.1016/j.ygyno.2018.07.020. Epub 2018 Aug 3.

12.

ESGO Survey on Current Practice in the Management of Cervical Cancer.

Dostalek L, Åvall-Lundqvist E, Creutzberg CL, Kurdiani D, Ponce J, Dostalkova I, Cibula D.

Int J Gynecol Cancer. 2018 Jul;28(6):1226-1231. doi: 10.1097/IGC.0000000000001314.

PMID:
29958236
13.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A.

Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28.

PMID:
29955143
14.

Differences in health care professionals' and cancer patients' views on sexual health issues.

Greimel E, Lanceley A, Oberguggenberger A, Nordin A, Kuljanic K, Schmalz C, Arraras JI, Chie W, Jensen PT, Tomaszewski KA, Creutzberg CL, Galalae R, Toelen H, Inwald EC, Bjelic-Radisic V; EORTC Quality of Life Group.

Psychooncology. 2018 Sep;27(9):2299-2302. doi: 10.1002/pon.4814. Epub 2018 Jul 3. No abstract available.

PMID:
29927000
15.

Investigators' response.

Nout RA, Powell ME, de Boer SM, Creutzberg CL.

Lancet Oncol. 2018 May;19(5):602. doi: 10.1016/S1470-2045(18)30279-1. No abstract available.

PMID:
29726377
16.

Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?

Creutzberg CL, Bosse T.

Ann Oncol. 2018 May 1;29(5):1081-1082. doi: 10.1093/annonc/mdy098. No abstract available.

PMID:
29668827
17.

ENdometrial cancer SURvivors' follow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial.

Ezendam NPM, de Rooij BH, Kruitwagen RFPM, Creutzberg CL, van Loon I, Boll D, Vos MC, van de Poll-Franse LV.

Trials. 2018 Apr 16;19(1):227. doi: 10.1186/s13063-018-2611-x.

18.

Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues.

Van Gool IC, Rayner E, Osse EM, Nout RA, Creutzberg CL, Tomlinson IPM, Church DN, Smit VTHBM, de Wind N, Bosse T, Drost M.

Clin Cancer Res. 2018 Jul 1;24(13):3197-3203. doi: 10.1158/1078-0432.CCR-18-0266. Epub 2018 Mar 20.

19.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

20.

Phase 1-3 of the cross-cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ-22.

Oberguggenberger AS, Nagele E, Inwald EC, Tomaszewski K, Lanceley A, Nordin A, Creutzberg CL, Kuljanic K, Kardamakis D, Schmalz C, Arraras J, Costantini A, Almont T, Wei-Chu C, Dehandschutter S, Winters Z, Greimel E; EORTC Quality of Life Group.

Cancer Med. 2018 Mar;7(3):635-645. doi: 10.1002/cam4.1338. Epub 2018 Feb 13.

21.

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.

de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; for PORTEC Study Group.

Ann Oncol. 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753.

22.

International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

van de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S, Daniëls L, Creutzberg CL, Cocks K, Malak S, Caocci G, Molica S, Chie W, Efficace F; EORTC Quality of Life Group.

Qual Life Res. 2018 Feb;27(2):333-345. doi: 10.1007/s11136-017-1718-y. Epub 2017 Nov 10.

23.

Ruthenium-106 brachytherapy for iris and iridociliary melanomas.

Marinkovic M, Horeweg N, Laman MS, Bleeker JC, Ketelaars M, Peters FP, Luyten GPM, Creutzberg CL.

Br J Ophthalmol. 2018 Aug;102(8):1154-1159. doi: 10.1136/bjophthalmol-2017-310688. Epub 2017 Nov 9.

PMID:
29122824
24.

Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma.

Depreeuw J, Stelloo E, Osse EM, Creutzberg CL, Nout RA, Moisse M, Garcia-Dios DA, Dewaele M, Willekens K, Marine JC, Matias-Guiu X, Amant F, Lambrechts D, Bosse T.

Clin Cancer Res. 2017 Dec 1;23(23):7232-7241. doi: 10.1158/1078-0432.CCR-17-0566. Epub 2017 Sep 22.

25.

Corrigendum to "Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification" [Eur J Cancer 78 (2017) 82-90].

Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, Ezendam NP, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, van der Aa MA.

Eur J Cancer. 2017 Oct;84:370. doi: 10.1016/j.ejca.2017.08.003. Epub 2017 Aug 23. No abstract available.

PMID:
28844347
26.

Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.

Van Gool IC, Ubachs JEH, Stelloo E, de Kroon CD, Goeman JJ, Smit VTHBM, Creutzberg CL, Bosse T.

Histopathology. 2018 Jan;72(2):248-258. doi: 10.1111/his.13338. Epub 2017 Oct 10.

PMID:
28795426
27.

Reply to M. Wissing et al.

Wiltink LM, Nout RA, Fiocco M, Creutzberg CL, Marijnen CAM.

J Clin Oncol. 2017 Jun 1;35(16):1862. doi: 10.1200/JCO.2017.72.6125. Epub 2017 Mar 13. No abstract available.

PMID:
28549229
28.

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Edmondson RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, Stelloo E, Nijman HW, Leary A, Auguste A, Mileshkin L, Pollock P, MacKay HJ, Powell ME, Bosse T, Creutzberg CL, Kitchener HC.

Gynecol Oncol. 2017 Aug;146(2):327-333. doi: 10.1016/j.ygyno.2017.05.014. Epub 2017 May 13.

PMID:
28511869
29.

A Controlled Study on Vaginal Blood Flow During Sexual Arousal Among Early-Stage Cervical Cancer Survivors Treated With Conventional Radical or Nerve-Sparing Surgery With or Without Radiotherapy.

Bakker RM, Pieterse QD, van Lonkhuijzen LRCW, Trimbos BJBMZ, Creutzberg CL, Kenter GG, de Kroon CD, Ter Kuile MM.

Int J Gynecol Cancer. 2017 Jun;27(5):1051-1057. doi: 10.1097/IGC.0000000000000986.

PMID:
28498243
30.

Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.

van Esterik M, Van Gool IC, de Kroon CD, Nout RA, Creutzberg CL, Smit VTHBM, Bosse T, Stelloo E.

Oncotarget. 2017 Apr 11;8(15):25542-25551. doi: 10.18632/oncotarget.16067.

31.

Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification.

Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, Ezendam NP, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, van der Aa MA.

Eur J Cancer. 2017 Jun;78:82-90. doi: 10.1016/j.ejca.2017.03.010. Epub 2017 Apr 14. Erratum in: Eur J Cancer. 2017 Oct;84:370.

PMID:
28415003
32.

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Jordanova ES, Adam J, Freeman-Mills L, Church DN, Creutzberg CL, De Bruyn M, Nijman HW, Bosse T.

Oncoimmunology. 2016 Dec 9;6(2):e1264565. doi: 10.1080/2162402X.2016.1264565. eCollection 2017.

33.

Sexual distress and associated factors among cervical cancer survivors: A cross-sectional multicenter observational study.

Bakker RM, Kenter GG, Creutzberg CL, Stiggelbout AM, Derks M, Mingelen W, Kroon CD, Vermeer WM, Ter Kuile MM.

Psychooncology. 2017 Oct;26(10):1470-1477. doi: 10.1002/pon.4317. Epub 2016 Dec 6.

PMID:
27862635
34.

A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer.

Bakker RM, Mens JW, de Groot HE, Tuijnman-Raasveld CC, Braat C, Hompus WC, Poelman JG, Laman MS, Velema LA, de Kroon CD, van Doorn HC, Creutzberg CL, Ter Kuile MM.

Support Care Cancer. 2017 Mar;25(3):729-737. doi: 10.1007/s00520-016-3453-2. Epub 2016 Oct 27.

35.

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer.

Stelloo E, Versluis MA, Nijman HW, de Bruyn M, Plat A, Osse EM, van Dijk RH, Nout RA, Creutzberg CL, de Bock GH, Smit VT, Bosse T, Hollema H.

Oncotarget. 2016 Jun 28;7(26):39885-39893. doi: 10.18632/oncotarget.9414.

36.

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.

ANZGOG and PORTEC Group, Blinman P, Mileshkin L, Khaw P, Goss G, Johnson C, Capp A, Brooks S, Wain G, Kolodziej I, Veillard AS, O'Connell R, Creutzberg CL, Stockler MR.

Br J Cancer. 2016 Nov 8;115(10):1179-1185. doi: 10.1038/bjc.2016.323. Epub 2016 Oct 20.

37.

Practical guidance for mismatch repair-deficiency testing in endometrial cancer.

Stelloo E, Jansen AML, Osse EM, Nout RA, Creutzberg CL, Ruano D, Church DN, Morreau H, Smit VTHBM, van Wezel T, Bosse T.

Ann Oncol. 2017 Jan 1;28(1):96-102. doi: 10.1093/annonc/mdw542.

PMID:
27742654
38.

Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome.

Marinkovic M, Horeweg N, Fiocco M, Peters FP, Sommers LW, Laman MS, Bleeker JC, Ketelaars M, Luyten GP, Creutzberg CL.

Eur J Cancer. 2016 Nov;68:106-113. doi: 10.1016/j.ejca.2016.09.009. Epub 2016 Oct 12.

PMID:
27741435
39.

Risk factors and treatment for recurrent vulvar squamous cell carcinoma.

Nooij LS, Brand FA, Gaarenstroom KN, Creutzberg CL, de Hullu JA, van Poelgeest MI.

Crit Rev Oncol Hematol. 2016 Oct;106:1-13. doi: 10.1016/j.critrevonc.2016.07.007. Epub 2016 Jul 25. Review.

40.

Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter?

Nooij LS, van der Slot MA, Dekkers OM, Stijnen T, Gaarenstroom KN, Creutzberg CL, Smit VT, Bosse T, van Poelgeest MI.

Eur J Cancer. 2016 Sep;65:139-49. doi: 10.1016/j.ejca.2016.07.006. Epub 2016 Aug 3. Review.

PMID:
27497345
41.

Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?

van de Sande MA, Creutzberg CL, van de Water S, Sharfo AW, Hoogeman MS.

Radiother Oncol. 2016 Sep;120(3):397-403. doi: 10.1016/j.radonc.2016.06.016. Epub 2016 Jul 21.

PMID:
27452411
42.

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7.

43.

Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial.

Jameson MG, McNamara J, Bailey M, Metcalfe PE, Holloway LC, Foo K, Do V, Mileshkin L, Creutzberg CL, Khaw P.

J Med Imaging Radiat Oncol. 2016 Aug;60(4):554-9. doi: 10.1111/1754-9485.12447. Epub 2016 Apr 5.

PMID:
27059658
44.

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.

Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT.

Clin Cancer Res. 2016 Aug 15;22(16):4215-24. doi: 10.1158/1078-0432.CCR-15-2878. Epub 2016 Mar 22.

45.

Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial.

Lutgens LC, Koper PC, Jobsen JJ, van der Steen-Banasik EM, Creutzberg CL, van den Berg HA, Ottevanger PB, van Rhoon GC, van Doorn HC, Houben R, van der Zee J.

Radiother Oncol. 2016 Sep;120(3):378-382. doi: 10.1016/j.radonc.2016.02.010. Epub 2016 Feb 17.

PMID:
26897513
46.

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.

Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, MacKay HJ, Leary A, Powell ME, Mileshkin L, Creutzberg CL, Smit VT, Bosse T.

Mod Pathol. 2016 Feb;29(2):174-81. doi: 10.1038/modpathol.2015.147. Epub 2016 Jan 8.

47.

Hyperbaric oxygen therapy for radiation-induced injury: evidence is needed.

Creutzberg CL.

Lancet Oncol. 2016 Feb;17(2):132-134. doi: 10.1016/S1470-2045(15)00534-3. Epub 2015 Dec 17. No abstract available.

48.

Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial.

de Boer SM, Nout RA, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, Oerlemans S, Putter H, Verhoeven-Adema KW, Nijman HW, Creutzberg CL.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):797-809. doi: 10.1016/j.ijrobp.2015.08.023. Epub 2015 Aug 18.

49.

Cancer of the corpus uteri.

Amant F, Mirza MR, Koskas M, Creutzberg CL.

Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S96-104. doi: 10.1016/j.ijgo.2015.06.005. No abstract available.

50.

Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios.

Lim K, Erickson B, Jürgenliemk-Schulz IM, Gaffney D, Creutzberg CL, Viswanathan A, Portelance L, Beriwal S, Wolfson A, Bosch W, De Los Santos J, Yashar C, Jhingran A, Varia M, El Naqa I, King B, Fyles A.

Pract Radiat Oncol. 2015 Nov-Dec;5(6):e557-65. doi: 10.1016/j.prro.2015.06.011. Epub 2015 Jul 2.

Supplemental Content

Loading ...
Support Center